Reports Q3 revenue $82.13M, consensus $80.25M. “The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind (MNKD) Corporation. “With the FDA’s acceptance for review of the Afrezza pediatric sBLA, the submission of the FUROSCIX ReadyFlow Autoinjector sNDA, and continued progress in the pipeline programs, we are executing across a diversified portfolio with significant growth opportunities ahead.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MNKD Earnings this Week: How Will it Perform?
- Strong Revenue Growth and Strategic Developments Support MannKind’s Buy Rating
- MannKind’s Afrezza: Promising Expansion and Growth Potential with FDA sBLA Acceptance
- MannKind announces U.S. FDA accepted sBLA for Afrezza Inhalation Powder
- MannKind Completes Acquisition of scPharma